Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus

Epilepsia. 2017 Jul;58(7):1199-1207. doi: 10.1111/epi.13787. Epub 2017 Jun 9.

Abstract

Objective: To evaluate acute and long-term effects of intravenous brivaracetam (BRV) and BRV + diazepam (DZP) combination treatment in a rat model of self-sustaining status epilepticus (SSSE).

Methods: Rats were treated with BRV (10 mg/kg) 10 min after initiation of perforant path stimulation (PPS) as early treatment; or BRV (10-300 mg/kg), DZP (1 mg/kg), or BRV (0.3-10 mg/kg) + DZP (1 mg/kg) 10 min after the end of PPS (established SSSE). Seizure activity was recorded electrographically for 24 h posttreatment (acute effects), and for 1 week at 6-8 weeks or 12 months' posttreatment (long-term effects). All treatments were compared with control rats using one-way analysis of variance (ANOVA) and Bonferroni's test, or Kruskal--Wallis and Dunn's multiple comparison tests, when appropriate.

Results: Treatment of established SSSE with BRV (10-300 mg/kg) resulted in dose-dependent reduction in SSSE duration and cumulative seizure time, achieving statistical significance at doses ≥100 mg/kg. Lower doses of BRV (0.3-10 mg/kg) + low-dose DZP (1 mg/kg) significantly reduced SSSE duration and number of seizures. All control rats developed spontaneous recurrent seizures (SRS) 6-8 weeks after SSSE, whereas seizure freedom was noted in 2/10, 5/10, and 6/10 rats treated with BRV 200 mg/kg, 300 mg/kg, and BRV 10 mg/kg + DZP, respectively. BRV (10-300 mg/kg) showed a dose-dependent trend toward reduction of SRS frequency, cumulative seizure time, and spike frequency, achieving statistical significance at 300 mg/kg. Combination of BRV (10 mg/kg) + DZP significantly reduced SRS frequency, cumulative seizure time, and spike frequency. In the 12-month follow-up study, BRV (0.3-10 mg/kg) + low-dose DZP markedly reduced SRS frequency, cumulative seizure time, and spike frequency, achieving statistical significance at some doses. Early treatment of SSSE with BRV 10 mg/kg significantly reduced long-term SRS frequency.

Significance: These findings support clinical evaluation of BRV for treatment of status epilepticus or acute repetitive seizures.

Keywords: Antiepileptic drug; Epilepsy; Neuronal injury; Perforant path stimulation; Seizures.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology*
  • Dentate Gyrus / drug effects
  • Dentate Gyrus / physiopathology
  • Diazepam / pharmacology*
  • Disease Models, Animal*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Electrodes, Implanted
  • Electroencephalography / drug effects*
  • Evoked Potentials / drug effects
  • Evoked Potentials / physiology
  • Infusions, Intravenous
  • Long-Term Care
  • Male
  • Perforant Pathway / drug effects
  • Perforant Pathway / physiopathology
  • Pyrrolidinones / pharmacology*
  • Rats
  • Rats, Wistar
  • Signal Processing, Computer-Assisted*
  • Status Epilepticus / drug therapy*
  • Status Epilepticus / physiopathology

Substances

  • Anticonvulsants
  • Pyrrolidinones
  • Diazepam
  • brivaracetam